0
Lung Cancer: Lung Cancer III |

Prevalence of Tissue EGFR Mutation in Patients of Adenocarcinoma Lung and Its Ability to Predict Response to Tyrosine Kinase Inhibitors

Ashutosh Dhanuka, MD; Anant Mohan, MD; Randeep Guleria, DM; Gopi Khilnani, MD; Karan Madan, DM; Vijay Hadda, MD; Alpana Saxena, MD
Author and Funding Information

All India Institute of Medical Sciences, New Delhi, India


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;150(4_S):724A. doi:10.1016/j.chest.2016.08.819
Text Size: A A A
Published online

Extract

SESSION TITLE: Lung Cancer III

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM

PURPOSE: To estimate the prevalence of tissue EGFR mutation in patients of adenocarcinoma lung and its predictive value on treatment response to TKIs

METHODS: Treatment naive patients of adenocarcinoma lung were recruited. Al patients underwent complete staging and tissue EGFR mutation analysis using DNA extraction and Polymerase chain reaction. Patients were treated with Gefitinib if they were EGFR positive and platinum based doublet chemotherapy if they were EGFR negative. Treatment response was evaluated after 3 months of Gefitinib / 4 cycles of chemotherapy by using CT-PET scan. Prevalence tissue EGFR was estimated and response correlation to EGFR mutation was done using student t-test

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543